Dalbavancin Reduces Hospital Stay and Improves Productivity for Patients with Acute Bacterial Skin and Skin Structure Infections: The ENHANCE Trial

Overview of attention for article published in Infectious Diseases and Therapy, November 2019

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (67th percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

policy: 1 policy source

twitter: 2 X users

Readers on

mendeley: 28 Mendeley

Summary Policy documents X

So far, Altmetric has seen 1 policy document that references this research output.

dalbavancin

Cited by Canadian Agency for Drugs and Technologies in Health on 23 Feb 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.